Welcome to Axentis Pharma

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives against chronic lung diseases and respiratory disorders, especially on cystic fibrosis. The company developed AX-TOBRA, a liposome-based drug-device combination product which received orphan designation in Europe and in the USA. Axentis won a final and binding arbitral award which was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis is seeking to enforce the award through judicial remedies.




 
Meet us at
July 6, 2016
Rheinfelden, Switzerland
Axentis Pharma AG
Annual General Meeting


October 4-6, 2016
Barcelona, Spain
CPhI Worldwide
www.cphi.com
Contact
Axentis Pharma AG
c/o Praxis und Kurszentrum Edith Aziz
Limmatquai 138
8001 Zurich
 

© 2016 Axentis Pharma AG Limmatquai 138, 8001 Zurich phone: +41 44 202 7878